Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

Bone Marrow Transplantation

Volumn 43, Issue 8, 2009, Pages 619-625

  Gertz, M A ^a   Kumar, S K ^a   Lacy, M Q ^a   Dispenzieri, A ^a   Hayman, S R ^a   Buadi, F K ^a   Dingli, D ^a   Gastineau, D A ^a   Winters, J L ^a   Litzow, M R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; LENALIDOMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; APHERESIS; ARTICLE; BACTEREMIA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN CELL; LENGTH OF STAY; LEUKOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETREATMENT; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

AGED; BLOOD PLATELETS; CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPHILS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349110824     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.369     Document Type: Article

References (35)

1. Bjorkstrand B, Gahrton G. High-dose treatment with autologous stem cell transplantation in multiple myeloma: Past, present, and future. Semin Hematol 2007; 44: 227-233.
2. Jagannath S. Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma 2007; 7(Suppl 5): S207-S214.
3. Bashey A, Donohue M, Liu L,Medina B, Corringham S, Ihasz A et al. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage- colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion 2007; 47: 2153-2160.
4. Jacoub JF, Suryadevara U, Pereyra V, Colon D, Fontelonga A, Mackintosh FR et al. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 2006; 34: 1443-1450.
5. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-697.
6. To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL et al Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-447.
7. Boiron JM, Marit G, Faberes C, Cony-Makhoul P, Foures C, Ferrer AM et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 1993; 12: 49-55.
8. Vescio RA, Han EJ, Schiller GJ, Lee JC, Wu CH, Cao J et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996; 18: 103-110.
9. + selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999; 93: 1858-1868.
10. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H et al Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-3779.
11. Hill QA, Buxton D, Pearce R, Gesinde MO, Smith GM, Cook G. An analysis of the optimal timing of peripheral blood stem cell harvesting following priming with cyclophosphamide and G-CSF. Bone Marrow Transplant 2007; 40: 925-930.
12. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161-167.
13. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384-388.
14. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N et al Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 605-611.
15. - fraction. Int J Artif Organs 1993; 16(Suppl 5): 83-88.
16. Burgstaler EA, Pineda AA, Winters JL. Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator. J Clin Apher 2004; 19: 103-111.
17. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
18. Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A et al Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001; 112: 242-247.
19. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042.
20. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N et al Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282-1284.
21. + selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma. Bone Marrow Transplant 2000; 25: 1175-1184.
22. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L et al Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
23. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther 2006; 6: 343-360.
24. Alegre A, Tomas JF, Martinez-Chamorro C, Gil-Fernandez JJ, Fernandez-Villalta MJ, Arranz R et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211-217.
25. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280-1281; author reply 1281-2.
26. Tarella C, Boccadoro M, Omede P, Bondesan P, Caracciolo D, Frieri R et al. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Bone Marrow Transplant 1993; 11: 271-277.
27. Scott MA, Ager S, Apperley JF, Jestice HK, Bloxham DM, Boraks P et al Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma. Leuk Lymphoma 1995; 19: 479-484.
28. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N et al Transplantation without growth factor: Engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplant 2007; 40: 989-993.
29. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059-2064.
30. Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, Dallorso S et al. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 1999; 27: 1460-1466.
31. Banfi A, Bianchi G, Galotto M, Cancedda R, Quarto R. Bone marrow stromal damage after chemo/radiotherapy: Occurrence, consequences and possibilities of treatment. Leuk Lymphoma 2001; 42: 863-870.
32. Corazza F, Hermans C, Ferster A, Fondu P, Demulder A, Sariban E. Bone marrow stroma damage induced by chemotherapy for acute lymphoblastic leukemia in children. Pediatr Res 2004; 55: 152-158.
33. Li J, Law HK, Lau YL, Chan GC. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol 2004; 127: 326-334.
34. Kushner BH, Gulati SC, O'Reilly RJ, Heller G, Cheung NK. Autografting with bone marrow exposed to multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxy-cyclophosphamide in vitro. Med Pediatr Oncol 1990; 18: 454-458.
35. Spyridonidis A, Kuttler T, Wasch R, Samek E, Waterhouse M, Behringer D et al. Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin. Stem Cells Dev 2005; 14 213-222.